Angiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension

Table 3 Multivariate Cox proportional risk model to investigate the association between discontinuation of angiotensin converting enzymes inhibitors or angiotensin receptor blockers and prognosis

	All the objects		Stratified by admission severity
			Moderate		Severe
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
ACEIs/ARBs	0.424 (0.187, 0.962)	0.040	0.224 (0.050, 0.998)	0.0497	0.793 (0.215, 2.926)	0.728
qSOFA score	0.455 (0.201, 1.026)	0.058	0.685 (0.112, 4.199)	0.682	0.576 (0.161, 2.053)	0.395
Gender	1.116 (0.527, 2.363)	0.774	0.733 (0.100, 5.368)	0.760	0.850 (0.267, 2.698)	0.782
Coronary heart disease	3.497 (1.475, 8.291)	0.004	2.207 (0.569, 8.562)	0.252	3.695 (0.933, 14.64)	0.063
Chest CT results pleural effusion	0.577 (0.187, 1.778)	0.338	0.348 (0.042, 2.871)	0.327	0.294 (0.037, 2.303)	0.244
Albumin	1.087 (0.969, 1.219)	0.153	1.110 (0.860, 1.433)	0.423	1.163 (0.970, 1.394)	0.104
LDH	0.997 (0.992, 1.002)	0.239	1.000 (0.988, 1.012)	0.982	0.995 (0.988, 1.001)	0.128
Creatinine	0.978 (0.959, 0.997)	0.026	0.958 (0.920, 0.997)	0.036	0.993 (0.964, 1.023)	0.660
D-dimer	0.972 (0.907, 1.043)	0.431	0.489 (0.147, 1.624)	0.243	0.963 (0.889, 1.042)	0.349
hs-CRP	0.999 (0.988, 1.009)	0.793	0.993 (0.963, 1.025)	0.670	1.000 (0.985, 1.016)	0.953
Serum ferritin	1.000 (0.999, 1.001)	0.998	1.001 (0.997, 1.006)	0.600	1.001 (1.000, 1.002)	0.172
IL2R	1.000 (0.999, 1.002)	0.485	1.000 (0.998, 1.003)	0.814	1.000 (0.999, 1.002)	0.722
Myoglobin	1.002 (0.995, 1.010)	0.489	1.014 (1.002, 1.026)	0.026	0.993 (0.983, 1.003)	0.153

ACEIs/ARBs: Angiotensin converting enzymes inhibitors or angiotensin receptor blockers; qSOFA: Quick sequential organ failure assessment; LDH: Lactate dehydrogenase; hs-CRP: High-sensitive C-reactive protein; IL-2R: Interleukin-2 receptor; HR: Hazard ratio; CI: Confidence interval.